Journal of Molecular Neuroscience

Journal of Molecular Neuroscience (commonly abbreviated as J. Mol. Neurosci.) is a peer-reviewed monthly published by Springer Nature that carries original research advancing understanding of the molecular structure, function and development of the nervous system. It was founded in March 1989 and the 2025 impact factor is 2.4.Journal of Molecular Neuroscience（常用缩写 J. Mol. Neurosci.）是施普林格自然出版的同行评审月刊，专门发表有助于理解神经系统分子结构、功能与发育的原创研究，1989 年 3 月创刊，2025 年影响因子为 2.4。^[1]

Scope

The journal is committed to the rapid publication of original findings that increase understanding of the molecular structure, function and development of the nervous system. The criteria for acceptance are scientific excellence, originality and relevance to the field of molecular neuroscience.该刊的宗旨是快速发表能增进对神经系统分子结构、功能与发育认识的原创发现，录用标准定为科学质量、原创性以及对分子神经科学的相关性三条。

• Emphasis on clinical relevance: manuscripts with clinical relevance are especially encouraged, since providing a means for accelerating the progression of basic research findings towards clinical application is one of the journal's stated aims.临床相关性取向：特别鼓励具有临床相关性的稿件，因为该刊的定位之一就是为基础研究结论更快地转入临床应用提供通道。*
• Ethics requirement: all experiments involving animal or human subjects must have been approved by the appropriate institutional review committee and must conform to accepted ethical standards.伦理要求：凡涉及动物或人体受试者的实验，均须事先获得相应机构审查委员会批准并符合公认的伦理标准。*
• Article types: original research articles form the core, accompanied by mini-reviews, novel gene discoveries and an accelerated route for articles of special interest.稿件类型：以原创研究论文为主，另设小篇幅综述与新基因发现栏目，并对具有特殊兴趣的稿件提供加速发表的通道。*
• Open access: the journal is hybrid, offering authors the choice of publishing at no charge under the subscription model or paying a publication charge to make the article immediately available to readers.开放获取：属混合开放获取模式，作者可在订阅模式下免费发表，或支付版面费使论文即时向读者开放，两条路径并存。*

History

• March 1989: the journal was founded at Birkhäuser Boston in Cambridge, with volume 1 issue 1 appearing in March as a slim journal issued three times a year.1989 年 3 月：在剑桥的 Birkhäuser Boston 创刊，第 1 卷第 1 期于 3 月出版，早期为每年三期的薄刊。*
• The 1990s: publication began with Birkhäuser Boston and moved in 1993 to Humana Press of Totowa, New Jersey. Frequency changed to quarterly between 1993 and 1996, then rose to six issues a year from 1997.1990 年代：先由 Birkhäuser Boston 出版，1993 年起转入总部设于新泽西州 Totowa 的 Humana Press，出版频率于 1993 至 1996 年间改为季刊，1997 年起增至每年六期。*
• 1999: the journal absorbed Molecular and Chemical Neuropathology, formerly titled Neurochemical Pathology, a title founded in 1983. The merger strengthened the journal's coverage of neuropathological subjects.1999 年：吸收了原名 Neurochemical Pathology 的 Molecular and Chemical Neuropathology，后者创刊于 1983 年，此次合并使该刊的神经病理学方向选题得到充实。*
• 2004 to 2013: the journal appeared nine times a year, a frequency it maintained for some years.2004 年至 2013 年：出版频率为每年九期，是一段时期内该刊长期沿用的出版节奏。*
• 2006 and 2010: Humana Press was acquired by Springer Nature in 2006 with its imprint retained, and the journal's publishing entity formally became Springer Science+Business Media from 2010. It moved to monthly publication in 2014, and publisher information now names a Springer Nature entity.2006 年与 2010 年：Humana Press 于 2006 年被施普林格自然收购并保留其品牌，该刊的出版主体自 2010 年起正式变为 Springer Science+Business Media；2014 年起改为月刊，出版方信息如今显示为 Springer Nature 旗下实体。*

Editors

The editorial operation is small but clearly divided. Beneath the Editor-in-Chief sits an Associate Editor, and board members are grouped into subject sections covering animal models, drug discovery and neurotechnology, neurochemistry, neurogenetics and neuroproteomics, and neurochemistry with neuroimmunology and neurophysiology, each section reviewing its own remit.该刊的编务规模不大但分工清晰，主编之下设副主编，编委成员按动物模型、药物发现与神经技术、神经化学、神经遗传学与神经蛋白质组学、神经化学与神经免疫及神经生理学等专题板块分组，各板块的审稿范围彼此分开。

• Editor-in-Chief: the Editor-in-Chief is Illana Gozes, Professor Emerita at the Faculty of Medicine and Health Sciences of Tel Aviv University and director of the Elton Laboratory, who also serves as president of the European Society for Neurochemistry.主编：现任主编为 Illana Gozes，特拉维夫大学医学与健康科学学院荣休教授，兼任 Elton 实验室主任，同时也是欧洲神经化学学会主席。*
• Associate Editors: the Associate Editors include Yong Cheng of Minzu University of China, whose research covers mechanisms and new treatment strategies for psychological and brain disorders, basic and translational work on rare diseases, and the mechanisms by which traditional Chinese medicines act in neurological and psychiatric illness.副主编：副主编包括任职于中央民族大学的 Yong Cheng，其研究方向为心理与脑疾病的发病机制与诊疗新策略、罕见病的基础与转化研究，以及中国传统药物在神经与精神疾病中的作用机制。*
• Board sections: the board is organised along the subject sections described above and includes scholars such as M. Flint Beal, Ashley I. Bush, George Fink, Roy Alcalay, Barbara Ranscht, D. A. Carter, Rudolph Tanzi, Tallie Z. Baram, Sue D. Brain, Yong Cheng, Richard Wurtman and Rami Yaka.编委分组：编委按前述专题板块分组，成员包括 M. Flint Beal、Ashley I. Bush、George Fink、Roy Alcalay、Barbara Ranscht、D. A. Carter、Rudolph Tanzi、Tallie Z. Baram、Sue D. Brain、Yong Cheng、Richard Wurtman 与 Rami Yaka 等学者。*
• Submission system: manuscripts are submitted through Springer's online system and undergo peer review, and experiments involving animal or human subjects require documentation of the approving review body.投稿系统：稿件经 Springer 旗下的在线系统提交并实行同行评审，涉及动物或人体受试者的实验须附审查批准文件。^[2]